188 related articles for article (PubMed ID: 24811271)
1. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients.
Kennedy RB; Ovsyannikova IG; Haralambieva IH; Lambert ND; Pankratz VS; Poland GA
Immunogenetics; 2014 Aug; 66(7-8):493-9. PubMed ID: 24811271
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination.
Voigt EA; Haralambieva IH; Larrabee BL; Kennedy RB; Ovsyannikova IG; Schaid DJ; Poland GA
J Infect Dis; 2018 Jan; 217(4):560-566. PubMed ID: 29253144
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms/haplotypes associated with multiple rubella-specific immune response outcomes post-MMR immunization in healthy children.
Ovsyannikova IG; Salk HM; Larrabee BR; Pankratz VS; Poland GA
Immunogenetics; 2015 Oct; 67(10):547-61. PubMed ID: 26329766
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination.
Kennedy RB; Ovsyannikova IG; Haralambieva IH; Lambert ND; Pankratz VS; Poland GA
Hum Genet; 2014 Nov; 133(11):1407-17. PubMed ID: 25098560
[TBL] [Abstract][Full Text] [Related]
5. Single-nucleotide polymorphism associations in common with immune responses to measles and rubella vaccines.
Ovsyannikova IG; Salk HM; Larrabee BR; Pankratz VS; Poland GA
Immunogenetics; 2014 Nov; 66(11):663-9. PubMed ID: 25139337
[TBL] [Abstract][Full Text] [Related]
6. Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population.
Dhiman N; Ovsyannikova IG; Vierkant RA; Pankratz VS; Jacobson RM; Poland GA
Tissue Antigens; 2008 Sep; 72(3):211-20. PubMed ID: 18715339
[TBL] [Abstract][Full Text] [Related]
7. Associations between single nucleotide polymorphisms in cellular viral receptors and attachment factor-related genes and humoral immunity to rubella vaccination.
Haralambieva IH; Lambert ND; Ovsyannikova IG; Kennedy RB; Larrabee BR; Pankratz VS; Poland GA
PLoS One; 2014; 9(6):e99997. PubMed ID: 24945853
[TBL] [Abstract][Full Text] [Related]
8. Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.
Tosh PK; Kennedy RB; Vierkant RA; Jacobson RM; Poland GA
Viral Immunol; 2009 Dec; 22(6):451-6. PubMed ID: 19951182
[TBL] [Abstract][Full Text] [Related]
9. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination.
Haralambieva IH; Ovsyannikova IG; Kennedy RB; Vierkant RA; Pankratz VS; Jacobson RM; Poland GA
Vaccine; 2011 Oct; 29(45):7883-95. PubMed ID: 21875636
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination.
Lambert ND; Haralambieva IH; Kennedy RB; Ovsyannikova IG; Pankratz VS; Poland GA
J Infect Dis; 2015 Mar; 211(6):898-905. PubMed ID: 25293367
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide determinants of cellular immune responses to mumps vaccine.
Ovsyannikova IG; Haralambieva IH; Schaid DJ; Warner ND; Poland GA; Kennedy RB
Vaccine; 2023 Oct; 41(44):6579-6588. PubMed ID: 37778899
[TBL] [Abstract][Full Text] [Related]
12. Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes.
White SJ; Haralambieva IH; Ovsyannikova IG; Vierkant RA; O'Byrne MM; Poland GA
Hum Immunol; 2012 Jun; 73(6):636-40. PubMed ID: 22504412
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine.
Haralambieva IH; Ovsyannikova IG; Umlauf BJ; Vierkant RA; Shane Pankratz V; Jacobson RM; Poland GA
Vaccine; 2011 Nov; 29(48):8988-97. PubMed ID: 21939710
[TBL] [Abstract][Full Text] [Related]
14. 2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.
Haralambieva IH; Dhiman N; Ovsyannikova IG; Vierkant RA; Pankratz VS; Jacobson RM; Poland GA
Hum Immunol; 2010 Apr; 71(4):383-91. PubMed ID: 20079393
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
J Infect Dis; 2005 Feb; 191(4):515-9. PubMed ID: 15655774
[TBL] [Abstract][Full Text] [Related]
16. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional signatures associated with rubella virus-specific humoral immunity after a third dose of MMR vaccine in women of childbearing age.
Haralambieva IH; Eberhard KG; Ovsyannikova IG; Grill DE; Schaid DJ; Kennedy RB; Poland GA
Eur J Immunol; 2021 Jul; 51(7):1824-1838. PubMed ID: 33818775
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination.
Haralambieva IH; Oberg AL; Ovsyannikova IG; Kennedy RB; Grill DE; Middha S; Bot BM; Wang VW; Smith DI; Jacobson RM; Poland GA
PLoS One; 2013; 8(5):e62149. PubMed ID: 23658707
[TBL] [Abstract][Full Text] [Related]
19. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.
Ovsyannikova IG; Dhiman N; Haralambieva IH; Vierkant RA; O'Byrne MM; Jacobson RM; Poland GA
Hum Genet; 2010 Feb; 127(2):207-21. PubMed ID: 19902255
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
